Pharmacogenetics Testing for Poor Response to Antidepressants: a Transnosographic Case Series

Overview

Journal Front Pharmacol

Date 2024 Oct 24

PMID 39444600

Authors

Marie-Agnes Lorvellec

Gilles Sipahimalani

Bertrand Lahutte

Herve Delacour

Antoine Baldacci

Emeric Saguin

Affiliations

Soon will be listed here.

Abstract

Introduction: Pharmacogenetics (PGx) holds promise for optimizing psychotropic medication use, with and identified as key genes in antidepressant treatment. However, few studies have explored the genetic variants of these genes in real-world settings for patients experiencing ineffectiveness or adverse drug reactions (ADRs) to antidepressants.

Methods: This case series includes 40 patients who underwent PGx testing due to antidepressant ineffectiveness or ADRs between June 2020 and April 2022. We describe the patients' demographic, clinical, and genetic characteristics and assess the value of PGx testing based on feedback from their psychiatrists.

Results: The most common diagnoses were major depressive disorder (60.0%) and post-traumatic stress disorder (30.0%). Ineffectiveness was reported in 65.0% of patients, ADRs in 2.5%, and both in 32.5%. The antidepressants involved included SSRIs (45.0%), SNRIs (27.5%), atypical antidepressants (20.0%), and tricyclics (17.5%). Only 17.5% of patients had normal and metabolic activity. Actionable genetic variants were identified in 22.0% of /-antidepressant-response pairs. PGx recommendations were followed in 92.7% of cases, with significant improvement in ADRs reported in 71.4% of patients and efficacy improvement in 79.5%.

Discussion: Our findings suggest that PGx testing can guide prescribing decisions for patients with antidepressant ineffectiveness or ADRs. The relatively high prevalence of genetic variants affecting pharmacokinetics supports the broader adoption of PGx testing in psychiatric practice.

References

Bousman C, Arandjelovic K, Mancuso S, Eyre H, Dunlop B . Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 2018; 20(1):37-47. DOI: 10.2217/pgs-2018-0142. View

Huddart R, Fohner A, Whirl-Carrillo M, Wojcik G, Gignoux C, Popejoy A . Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research. Clin Pharmacol Ther. 2018; 105(5):1256-1262. PMC: 6465129. DOI: 10.1002/cpt.1322. View

Solomon H, Cates K, Li K . Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?. Psychiatry Res. 2018; 271:604-613. DOI: 10.1016/j.psychres.2018.12.053. View

Ingelman-Sundberg M . Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2004; 5(1):6-13. DOI: 10.1038/sj.tpj.6500285. View

Oslin D, Lynch K, Shih M, Ingram E, Wray L, Chapman S . Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022; 328(2):151-161. PMC: 9277497. DOI: 10.1001/jama.2022.9805. View

Perez V, Salavert A, Espadaler J, Tuson M, Saiz-Ruiz J, Saez-Navarro C . Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry. 2017; 17(1):250. PMC: 5513031. DOI: 10.1186/s12888-017-1412-1. View

Baldacci A, Saguin E, Annette S, Lahutte B, Colas M, Delacour H . [Cytochrome pharmacogenetics applied to the prescription of antidepressants: Instructions for use]. Encephale. 2022; 48(4):462-471. DOI: 10.1016/j.encep.2021.12.008. View

Rush A, Trivedi M, Wisniewski S, Nierenberg A, Stewart J, Warden D . Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163(11):1905-17. DOI: 10.1176/ajp.2006.163.11.1905. View

Kee P, Maggo S, Kennedy M, Chin P . The pharmacogenetics of and in a case series of antidepressant responses. Front Pharmacol. 2023; 14:1080117. PMC: 9988947. DOI: 10.3389/fphar.2023.1080117. View

10.

Chodavadia P, Teo I, Poremski D, Fung D, Finkelstein E . Prevalence and economic burden of depression and anxiety symptoms among Singaporean adults: results from a 2022 web panel. BMC Psychiatry. 2023; 23(1):104. PMC: 9925363. DOI: 10.1186/s12888-023-04581-7. View

11.

Huezo-Diaz P, Perroud N, Spencer E, Smith R, Sim S, Virding S . CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol. 2011; 26(3):398-407. DOI: 10.1177/0269881111414451. View

12.

Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol W . Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry. 2015; 206(2):93-100. DOI: 10.1192/bjp.bp.114.148551. View

13.

Swen J, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee A, Mulder H . Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther. 2011; 89(5):662-73. DOI: 10.1038/clpt.2011.34. View

14.

Bousman C, Stevenson J, Ramsey L, Sangkuhl K, Hicks J, Strawn J . Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023; 114(1):51-68. PMC: 10564324. DOI: 10.1002/cpt.2903. View

15.

Mishra S, Swain T, Mohanty M . Adverse drug reaction monitoring of antidepressants in the psychiatry outpatients department of a tertiary care teaching hospital. J Clin Diagn Res. 2013; 7(6):1131-4. PMC: 3708214. DOI: 10.7860/JCDR/2013/4985.3041. View

16.

Han C, Wang S, Bahk W, Lee S, Patkar A, Masand P . A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clin Psychopharmacol Neurosci. 2018; 16(4):469-480. PMC: 6245286. DOI: 10.9758/cpn.2018.16.4.469. View

17.

Chang M, Tybring G, Dahl M, Lindh J . Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin Pharmacokinet. 2014; 53(9):801-11. DOI: 10.1007/s40262-014-0162-1. View

18.

Schenk P, van Vliet M, Mathot R, van Gelder T, Vulto A, van Fessem M . The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. Pharmacogenomics J. 2009; 10(3):219-25. DOI: 10.1038/tpj.2009.50. View

19.

Hicks J, Bishop J, Sangkuhl K, Muller D, Ji Y, Leckband S . Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015; 98(2):127-34. PMC: 4512908. DOI: 10.1002/cpt.147. View

20.

Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pesic V, Molden E . Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020; 78(3):270-280. PMC: 7702196. DOI: 10.1001/jamapsychiatry.2020.3643. View